Circadian chronotherapy for human cancers

Lancet Oncology

Volumn 2, Issue 5, 2001, Pages 307-315

  Lévi, Francis ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHRONOTHERAPY; HUMAN; MORTALITY; NEOPLASM; PROGNOSIS; REVIEW; TIME;

ANTINEOPLASTIC AGENTS; CHRONOTHERAPY; HUMANS; NEOPLASMS; PROGNOSIS; TIME FACTORS;

EID: 0035353082     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00326-0     Document Type: Review

References (66)

1. Lévi F. Chronopharmacology of anticancer agents. Redfern P.H., Lemmer B. Handbook of Experimental Pharmacology: Physiology and Pharmacology of Biological Rhythms. 1997;299-331 Springer-Verlag, Berlin.
2. Mormont M.C., Hecquet B., Bogdan A., et al. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer. 78:1998;421-424.
3. Balsalobre A., Damiola F., Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell. 93:1998;929-937.
4. Dunlap J.C. Molecular bases for circadian clocks. Cell. 96:1999;271-290.
5. Shearman L.P., Sriram S., Weaver D.R., et al. Interacting molecular loops in the mammalian circadian clock. Science. 288:2000;1013-1019.
6. Moore R.Y. Entrainment pathways and the functional organization of the circadian system. Prog Brain Res. 111:1996;103-119.
7. Cassone V.M. Melatonin's role in vertebrate circadian rhythms. Chronobiol Int. 15:1998;457-473.
8. Boughattas N., Lévi F., Fournier C., et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res. 49:1989;3362-3368.
9. Ohdo S., Makinosumi T., Ishizaki T., et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol Exp Ther. 283:1997;1383-1388.
10. Boughattas N., Lévi F., Fournier C., et al. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice. J Pharm Exp Ther. 255:1990;672-679.
11. Zhang R., Lu Z., Liu T., et al. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res. 53:1993;2816-2822.
12. Li X.M., Metzger G., Filipski E., et al. Pharmacologic modulation of reduced glutathione (GSH) circadian rhythms by buthionine sulfoximine (BSO): relationship with cisplatin (CDDP) toxicity in mice. Toxicol Appl Pharmacol. 143:1997;281-290.
13. Tampellini M., Filipski E., Liu X.-H., et al. Circadian rhythm in docetaxel tolerability and efficacy in mice. Cancer Res. 58:1998;3896-3904.
14. Focan C. Circadian rhythms and cancer chemotherapy. Pharmacol Ther. 67:1995;1-52.
15. Filipski E., Amat S., Lemaigre G., et al. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J Pharm Exp Ther. 289:1999;231-235.
16. Sothern R., Lévi F., Haus E., et al. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 81:1989;135-145.
17. D'attino R.M., Filipski E., Granda T.G., et al. Irinotecan (CPT-11) and oxaliplatin (l-OHP) synergistic activity at specific circadian times in tumor-bearing mice. Proc Am Assoc Cancer Res (abstr). 91:2000;1268.
18. Granda T.G., Filipski E., D'Attino R.M., et al. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res. 61:2001;1996-2001.
19. Smaaland R., Laerum O.D., Lote K., et al. DNA synthesis in human bonne marrow is circadian stage dependent. Blood. 77:1991;2603-2611.
20. Bjarnason G.A., Jordan R.C.K., Sothern R.B. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 154:1999;613-622.
21. Bjarnason G.A., Jordan R.C.K., Wood P.A., et al. Circadian expression of clock genes in human oral epithelium and skin: association with cell cycle progression. Am J Pathol 2000 (in press).
22. Harris B., Song R., Soong S., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50:1990;197-201.
23. Langouët A.M., Metzger G., Comisso M., et al. Plasma concentration of 5-fluorouracil and mononuclear cell dihydropyrimidine dehydrogenase activity in patients treated with different chronomodulated schedules. Biol Rhythm Res(abstr). 26:(409):1995;135.
24. Lévi F., Giacchetti S. Chronomodulation of chemotherapy against metastatic colorectal cancer. In: Bleiberg H., Kemeny N., Rougier P.H., Wilke H.J. (Eds). Colorectal cancer: a clinical guide to therapy. London: Martin Dunitz Publishers 2001 (in press).
25. Petit E., Milano G., Lévi F., et al. Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients. Cancer Res. 48:1988;1676-1679.
26. Metzger G., Massari C., Etienne M.C., et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharm Ther. 56:1994;190-201.
27. Bressolle F., Joulia J.M., Pinguet F., et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 44:1999;295-302.
28. Codacci-Pisanelli G., van der Wilt C.L., Pinedo H.M., et al. Antitumor activity, toxicity and inhibition of thymidylate synthase of prolonged administration of 5-fluorouracil in mice. Eur J Cancer. 31A:1995;1517-1525.
29. Takimoto C.H., Yee L.K., Venzon D.J., et al. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion. Clin Cancer Res. 5:1999;1347-1352.
30. King D.P., Zaho Y., Sangoram A.M., et al. Positional cloning of the mouse circadian clock gene. Cell. 89:1997;641-653.
31. Halberg F., Cornelissen G., Sothern R.B., et al. International geographic studies of oncological interest on chronobiological variables. Kaiser H.E. Neoplasms - comparative pathology of growth in animals, plants and man. 1981;553-596 Williams & Wilkins, Baltimore.
32. Mormont M.C., Lévi F. ircadian-system alterations during cancer processes: a review. Int J Cancer. 70:1997;241-247.
33. Hrushesky W. Circadian timing of cancer chemotherapy. Science. 228:1985;73-75.
34. Lévi F., Benavides M., Chevelle C., et al. Therapy of advanced ovarian cancer with 4'-0-tetrahydropyranyl doxorubicin (THP) and cisplatin: a phase II trial with an evaluation of circadian timing and dose intensity. J Clin Oncol. 8:1990;705-714.
35. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 16:1998;301-308.
36. Adler S., Lang S., Langenmayer I., et al. Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. Cancer. 73:1994;2905-2912.
37. Falcone A., Allegrini G., Antonuzzo A., et al. Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery. Oncology. 57:1999;195-201.
38. Roemeling R.V., Hrushesky W.M. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol. 7:1989;1710-1719.
39. Lévi F., Misset J.L., Brienza S., et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 69:1992;893-900.
40. Giacchetti S., Zidani R., Goldwasser F., et al. Chronomodulated CPT-11: a pilot study (abstr). Proc Am Soc Clin Oncol. 18:1999;259a.
41. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 16:1989;215-237.
42. Lévi F., Metzger G., Massari C., Milano G. Oxaliplatin. Pharmacokinetics and chronopharmacological aspects. Clinical Pharmacokinet. 36:2000;1-21.
43. Garufi C., Lévi F., Aschelter A.M., et al. A Phase I trial of five day chronomodulated infusion of 5-fluorouracil and l-folinic acid in patients with metastatic colorectal cancer. Eur J Cancer. 33:1997;1566-1571.
44. Lévi F., Zidani R., Misset J.L. for the International Organization for Cancer Chronotherapy: randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
45. Lévi F., Zidani R., Brienza S., et al. for the International Organization for Cancer Chronotherapy: A multicentre evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal cancer. Cancer. 85:1999;2532-2540.
46. Giacchetti S., Perpoint B., Zidani R., et al. International Organization of Cancer: phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil - leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 18:2000;136-147.
47. Curé H., Pezet D., Kwiatkowski F., et al. 5-fluorouracil (5-FU) and l-folinic acid (l-FA) pharmacokinetics during chronomodulated (CM) delivery. International Conference on Chemotherapeutic Strategies for Treatment of Colorectal Cancer. Amsterdam, February 10-12, 1999.
48. Jolivet J., Létourneau Y. Colorectal cancer chronotherapy: implementation in general hospitals and clinical results. Biological clocks: mechanisms and applications. Touitou Y. Proc Int Cong Chronobiol. 1152:1998;483-490 Elsevier. International Congress Series, Amsterdam.
49. Bertheault-Cvitkovic F., Jami A., Ithzaki M., et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 14:1996;2950-2958.
50. Giacchetti S., Itzhaki M., Gruia G., et al. Long term survival of patients with unresectable colorectal liver metastases following infusional chemotherapy with 5-fluorouracil, folinic acid, oxaliplatin and surgery. Ann Oncol. 10:1999;1-7.
51. Lévi F., Zidani R., Llory J.F., et al. International Organization for Cancer Chronotherapy: final efficacy update at 7 years of flat vs chronomodulated infusion (chrono) of oxaliplatin, 5-fluorouracil and leucovorin as first line treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol (abstr 936). 19:2000;242a.
52. Stangl R., Altendorf-Hofmann A., Charnley R.M., Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 343:1994;1405-1410.
53. Mormont M.C., Waterhouse J., Bleuzen P., et al. Marked 24-h rest-activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 6:2000;3038-3045.
54. Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 92:2000;994-1000.
55. Ticher A., Haus E., Ron I.G., et al. The pattern of hormonal circadian time structure (acrophase) as an assessor of bresat-cancer risk. Int J Cancer. 65:1996;591-593.
56. Rafnsson V., Hrafnkelsson J., Tulinius H. Incidence of cancer among commercial airline pilots. Occup Environ Med. 57:2000;175-179.
57. Ballard T., Lagorio S., De Angelis G., Verdecchia A. Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med. 71:2000;216-224.
58. Shah P.N., Mhatre M.L., Kothari L. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res. 44:1984;3403-3407.
59. van den Heiligenberg S., Deprés-Brummer P., Barbason H., et al. Promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sciences. 64:1999;2523-2534.
60. Buyse M., Thirion P., Carlson R.W., et al. Meta-Analysis Group in Cancer. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet. 356:2000;373-378.
61. Rivard G., Infante-Rivard C., Hoyeux C., Champagne J. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: better in the evening. Lancet. 2:1985;1264-1266.
62. Schmiegelow K., Glomstein A., Kristinsson J., et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 19:1997;102-109.
63. Bjarnason G.A., Jordan R. Circadian variation of cell proliferation and cell protein expression in man: clinical implications. Meijer L., Jézéquel A., Ducommun B. Progress in cell cycle research. 4:2000;193-206 Kluwer Academic Publishers, New York.
64. Lévi F., Bourin P., Deprés-Brummer P., Adam R. Chronobiology of the immune system. Implication for the delivery of therapeutic agents. Clin Immunother. 2:1994;53-64.
65. Lévi F., Soussan A., Adam R., et al. A phase I-II trial of a five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Infus Chemother. 5:1995;153-158.
66. Caussanel J.P., Levi F., Brienza S., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 82:1990;1046-1050.